Rapid Dose Therapeutics Advances Collaboration with Global Leader for Market-Ready QuickStrip(R) Nicotine in 2025
Rapid Dose Therapeutics (CSE: DOSE) has expanded its collaboration with an unnamed international company in oral nicotine products through an exclusive pre-commercialization agreement extending to June 19, 2025. The agreement involves RDT providing project management and product development services for a monthly fee of USD$120,000.
The collaboration, which began in December 2022, focuses on finalizing innovative, market-ready products for launch in 2025. Key development areas include formulation optimization, packaging enhancement, consumer studies, product benchmarking, and regulatory documentation preparation. The partnership leverages RDT's proprietary QuickStrip™ Oral Thin Film (OTF) technology to develop next-generation smoke-free alternatives.
Rapid Dose Therapeutics (CSE: DOSE) ha ampliato la sua collaborazione con un'azienda internazionale non identificata nel settore dei prodotti a base di nicotina orale tramite un accordo esclusivo di pre-commercializzazione che si estende fino al 19 giugno 2025. L'accordo prevede che RDT fornisca servizi di gestione del progetto e sviluppo del prodotto per una tassa mensile di 120.000 USD.
La collaborazione, iniziata a dicembre 2022, si concentra sulla finalizzazione di prodotti innovativi pronti per il mercato da lanciare nel 2025. Le principali aree di sviluppo comprendono l'ottimizzazione delle formulazioni, il miglioramento del packaging, studi sui consumatori, benchmarking dei prodotti e preparazione della documentazione normativa. Il partenariato sfrutta la tecnologia proprietaria di RDT, QuickStrip™ Oral Thin Film (OTF), per sviluppare alternative di nuova generazione senza fumo.
Rapid Dose Therapeutics (CSE: DOSE) ha ampliado su colaboración con una compañía internacional sin nombre en productos de nicotina oral mediante un acuerdo exclusivo de pre-comercialización que se extiende hasta el 19 de junio de 2025. El acuerdo implica que RDT proporcionará servicios de gestión de proyectos y desarrollo de productos por una tarifa mensual de 120,000 USD.
La colaboración, que comenzó en diciembre de 2022, se centra en la finalización de productos innovadores listos para el mercado para su lanzamiento en 2025. Las áreas clave de desarrollo incluyen la optimización de formulaciones, mejora de empaque, estudios de consumidores, comparación de productos y preparación de documentación regulatoria. La asociación aprovecha la tecnología propietaria de RDT, QuickStrip™ Oral Thin Film (OTF), para desarrollar alternativas de próxima generación sin humo.
Rapid Dose Therapeutics (CSE: DOSE)는 이름이 밝혀지지 않은 국제 회사와 구강 니코틴 제품에 대한 협력을 확대하고 있으며, 이는 2025년 6월 19일까지 지속되는 독점적인 사전 상용화 계약을 통해 이루어집니다. 계약에 따라 RDT는 매월 120,000 USD의 요금으로 프로젝트 관리 및 제품 개발 서비스를 제공합니다.
2022년 12월에 시작된 이번 협력은 2025년 출시를 위한 혁신적이고 시장 준비가 완료된 제품의 최종 단계를 목표로 하고 있습니다. 주요 개발 영역에는 포뮬레이션 최적화, 패키징 개선, 소비자 연구, 제품 벤치마킹 및 규제 문서 준비가 포함됩니다. 이 파트너십은 RDT의 독점 기술인 QuickStrip™ Oral Thin Film (OTF)을 활용하여 차세대 무연 대안을 개발합니다.
Rapid Dose Therapeutics (CSE: DOSE) a élargi sa collaboration avec une entreprise internationale non nommée dans le domaine des produits à la nicotine orale grâce à un accord exclusif de pré-commercialisation valable jusqu'au 19 juin 2025. Cet accord implique que RDT fournisse des services de gestion de projet et de développement de produit pour un tarif mensuel de 120 000 USD.
La collaboration, qui a débuté en décembre 2022, est axée sur la finalisation de produits innovants prêts à être commercialisés pour un lancement en 2025. Les principaux axes de développement comprennent l'optimisation des formulations, l'amélioration de l'emballage, les études de consommateurs, le benchmarking des produits et la préparation de la documentation réglementaire. Ce partenariat tire parti de la technologie exclusive de RDT, QuickStrip™ Oral Thin Film (OTF), pour développer de nouvelles alternatives sans fumée de prochaine génération.
Rapid Dose Therapeutics (CSE: DOSE) hat die Zusammenarbeit mit einem nicht genannten internationalen Unternehmen im Bereich der oralen Nikotinprodukte durch einen exklusiven Vorabvermarktungsvertrag bis zum 19. Juni 2025 erweitert. Der Vertrag sieht vor, dass RDT Projektmanagement- und Produktentwicklungsdienste gegen eine monatliche Gebühr von 120.000 USD bereitstellt.
Die Zusammenarbeit, die im Dezember 2022 begann, konzentriert sich auf die Finalisierung innovativer, marktreifer Produkte für die Einführung im Jahr 2025. Zu den wichtigsten Entwicklungsbereichen gehören die Formulierungsoptimierung, die Verbesserung der Verpackung, Verbraucherstudien, Produkterfassung und die Vorbereitung von regulatorischen Dokumenten. Die Partnerschaft nutzt RDTs proprietäre QuickStrip™ Oral Thin Film (OTF)-Technologie zur Entwicklung neuester rauchfreier Alternativen.
- Secured monthly revenue stream of USD$120,000 through June 2025
- Partnership with established international company in FDA-approved smoke-free products
- Potential commercial agreement following pre-commercialization phase
- Partner company remains anonymous, creating uncertainty
- No guaranteed commercial agreement beyond June 2025
- Revenue dependent on single partnership agreement
Burlington, Ontario--(Newsfile Corp. - January 28, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (RDT), a Canadian biotechnology company working with an international company in oral nicotine products, is pleased to announce the expansion of their collaboration through the continuation of the exclusive pre-commercialization agreement. This agreement aims to finalize the development of innovative, market-ready products projected for launch in 2025. The pre-commercialization agreement requires RDT to provide project management and product development services in exchange for a monthly fee of USD
Building on a relationship that began in December 2022, this final phase of collaboration underscores the commitment of both companies to deliver innovative solutions that meet evolving consumer needs. Enhancing and optimizing the formulation and packaging, completing consumer studies, benchmarking against current products, and preparing documentation for regulators are the key elements to be finalized by June 19, 2025.
RDT, renowned for its proprietary QuickStrip™ delivery system, has been working closely with this international company, who has created and marketed FDA approved smoke-free alternatives, to develop novel products designed to enhance user experiences.
"This expanded collaboration is an important strategic opportunity for RDT," said Mark Upsdell, CEO of Rapid Dose Therapeutics. "We prioritize research and development and are proud to partner with this future-focused company. We are committed to playing a leadership role in leveraging science and our unique QuickStrip™ Oral Thin Film (OTF) technology to develop next-generation products that are tailored to global market demands."
RDT is focused on delivering breakthrough innovations that align with the vision of a smoke-free future. Through this pre-commercialization agreement, the two companies are set to combine their respective expertise in consumer behavior, product development, and market research to ensure the products are positioned for success.
"This agreement reinforces our dedication to providing consumers with science-based alternatives to smoking," stated Mark Upsdell. "We look forward to finalizing the development of these unique products and bringing them to market in 2025, contributing to our broader goal of transitioning adult smokers to safer alternatives."
The products developed under this collaboration are expected to leverage RDT's fast-acting oral delivery system combined with consumer insights and extensive global reach. The joint efforts are aimed at delivering innovative products that meet the highest standards of quality and safety.
As both companies work towards completing the pre-commercialization milestones in early 2025, as well as the anticipated formal commercial agreement, they are committed to maintaining the highest level of scientific rigor in the product development process, ensuring that these new offerings are both safe and effective for adult consumers worldwide.
About Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics Corp. (RDT) is a Canadian biotechnology company focused on innovative drug delivery solutions. Its flagship product, QuickStrip™, is a proprietary oral thin film that delivers active ingredients quickly and efficiently, offering fast-acting benefits to consumers in a variety of sectors. For more information about the Company, visit www.rapid-dose.com.
Media Contact:
Rapid Dose Therapeutics Corp.
Mark Upsdell CEO,
investorrelations@rapid-dose.com
Phone 416-477-1052
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-Looking statements are often identified by terms such as "intend", "may", "should", "anticipate", "expect", "potential", "believe", "intend", "will", "could", "are planned to", "are expected to" or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-Looking statements necessarily involve known and unknown risks, including, without limitation, the ability of RDT to work together with its international collaborator in the nicotine segment, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-Looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/238801
FAQ
What is the value of RDT's (RDTCF) new pre-commercialization agreement?
When will RDT's (RDTCF) new nicotine products launch?
What is the duration of RDT's (RDTCF) pre-commercialization agreement?
What technology is RDT (RDTCF) using for its nicotine products?
